Why ResMed (RMD) Stock Is Up Today

ResMed Inc. (RMD) is up 4.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely near-term catalyst is a bullish analyst upgrade issued Tuesday, which highlighted improving sleep-device growth and stronger earnings potential. Supportive fundamentals were already in place after ResMed posted solid fourth-quarter results, outlined a large shareholder return plan, and began a sizable accelerated share repurchase program.

Details:

An analyst upgraded ResMed to an outperform-equivalent rating and lifted its price target, pointing to stronger growth prospects in sleep devices and a favorable earnings outlook.

In its latest quarterly release, ResMed reported fourth-quarter revenue growth of 9% to about $1.46 billion and non-GAAP diluted earnings per share growth of 16% to $2.95.

Management said it expects to return more than $1.85 billion to shareholders during fiscal 2027 through buybacks and dividends, including a 10% dividend increase.

A September SEC filing disclosed a $450 million accelerated share repurchase agreement, funded with MatrixCare sale proceeds and cash on hand, which can reinforce investor confidence.

Sources:

SEC, ResMed, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$RMD Insider Trading Activity

$RMD insiders have traded $RMD stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.

Here’s a breakdown of recent trading of $RMD stock by insiders over the last 6 months:

MICHAEL J. FARRELL (Chairman and CEO) has made 0 purchases and 5 sales selling 24,955 shares for an estimated $5,321,108.
PETER C FARRELL has made 0 purchases and 3 sales selling 10,970 shares for an estimated $2,477,688.
BRETT SANDERCOCK (Chief Financial Officer) sold 1,000 shares for an estimated $224,310

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$RMD Hedge Fund Activity

We have seen 387 institutional investors add shares of $RMD stock to their portfolio, and 579 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,222,473 shares (+inf%) to their portfolio in Q2 2026, for an estimated $238,235,538
JPMORGAN CHASE & CO added 833,536 shares (+inf%) to their portfolio in Q2 2026, for an estimated $162,439,495
MORGAN STANLEY removed 757,890 shares (-28.2%) from their portfolio in Q2 2026, for an estimated $147,697,603
FIRST TRUST ADVISORS LP added 740,871 shares (+48.2%) to their portfolio in Q2 2026, for an estimated $144,380,940
BANK OF NEW YORK MELLON CORP removed 727,776 shares (-14.8%) from their portfolio in Q2 2026, for an estimated $141,828,986
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 679,489 shares (+150.9%) to their portfolio in Q2 2026, for an estimated $132,418,816
AMUNDI added 587,872 shares (+123.9%) to their portfolio in Q1 2026, for an estimated $131,965,506

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$RMD Congressional Stock Trading

Members of Congress have traded $RMD stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $RMD stock by members of Congress over the last 6 months:

SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$RMD Analyst Ratings

Wall Street analysts have issued reports on $RMD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JP Morgan issued a "Overweight" rating on 04/15/2026

To track analyst ratings and price targets for $RMD, check out Quiver Quantitative's $RMD forecast page.

$RMD Price Targets

Multiple analysts have issued price targets for $RMD recently. We have seen 6 analysts offer price targets for $RMD in the last 6 months, with a median target of $268.0.

Here are some recent targets:

Nathan Treybeck from Wells Fargo set a target price of $225.0 on 07/08/2026
Craig Wong-Pan from RBC Capital set a target price of $276.0 on 07/08/2026
Justin Patterson from Keybanc set a target price of $266.0 on 06/22/2026
David Bailey from Morgan Stanley set a target price of $230.0 on 06/17/2026
Laura Sutcliffe from Citigroup set a target price of $270.0 on 06/15/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.